NCT05915104View on ClinicalTrials.gov

Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2026

Conditions

Microscopic Colitis

Interventions

DRUG

Budesonide MMX®

9 mg delayed and extended-release tablet once daily

DRUG

Budesonide controlled ileal release (CR) capsules

three 3 mg capsules daily oral administration for 8 weeks

Sponsors

Collaborators (1)

Ferring Pharmaceuticals

All Listed Sponsors

collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

University of Calgary

OTHER

NCT05915104 - Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis | Biotech Hunter | Biotech Hunter